stoxline Quote Chart Rank Option Currency Glossary
  
VolitionRx Limited (VNRX)
0.4948  -0.005 (-1.04%)    05-12 16:00
Open: 0.481
High: 0.4982
Volume: 266,961
  
Pre. Close: 0.5
Low: 0.485
Market Cap: 50(M)
Technical analysis
2025-05-12 4:22:50 PM
Short term     
Mid term     
Targets 6-month :  0.64 1-year :  0.73
Resists First :  0.54 Second :  0.62
Pivot price 0.49
Supports First :  0.41 Second :  0.34
MAs MA(5) :  0.5 MA(20) :  0.49
MA(100) :  0.56 MA(250) :  0.62
MACD MACD :  -0.1 Signal :  -0.1
%K %D K(14,3) :  51.9 D(3) :  61.7
RSI RSI(14): 45.2
52-week High :  0.89 Low :  0.41
Price, MAs and Bollinger Bands

Price has closed below its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is BEARISH in short-term; and BEARISH in mid-long term.
[ VNRX ] has closed above bottom band by 38.7%. Bollinger Bands are 24.8% narrower than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.

Stock Price Prediction
If tomorrow: Open lower Open higher
High: 0.5 - 0.5 0.5 - 0.5
Low: 0.48 - 0.48 0.48 - 0.48
Close: 0.48 - 0.49 0.49 - 0.49
Company Description

VolitionRx Limited, a multi-national epigenetics company, engages in the development of blood tests to help diagnose a range of cancers and other diseases worldwide. It sells Nu.Q that detect cancer; Nu.Q Nets, monitoring the immune system; Nu.Q Vet cancer screening test for veterinary applications; Nu.Q Capture capturing and concentrating samples for more accurate diagnosis; and Nu.Q Discover, a solution to profiling nucleosomes. The company operates Nucleosomics a technology platform for blood test. VolitionRx Limited is based in Austin, Texas.

Headline News

Mon, 12 May 2025
VolitionRx Limited Schedules First Quarter 2025 Earnings Conference Call and Business Update | VNRX Stock News - GuruFocus

Mon, 12 May 2025
VolitionRx Limited Schedules First Quarter 2025 Earnings Conference Call and Business Update - Yahoo Finance

Mon, 12 May 2025
VolitionRx Limited Schedules First Quarter 2025 Earnings Conference Call and Business Update - Stock Titan

Wed, 07 May 2025
VolitionRX Limited: Outlines broad strategy to become the 'NETs company' worldwide through licensing and updates progress of Nu.Q® NETs test adoption | VNRX Stock News - GuruFocus

Wed, 07 May 2025
VolitionRx Updates Progress Of Nu.Q NETs Test Adoption - marketscreener.com

Wed, 07 May 2025
VolitionRX Limited: Outlines broad strategy to become the 'NETs company' worldwide through licensing and updates progress of Nu.Q® NETs test adoption - Yahoo Finance

Financial Analysis
Price to Book Value:
P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly.
Underperform
Price to Earnings:
PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS).
Underperform
Discounted cash flow:
DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows.
Underperform
Return on Assets:
ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit.
Underperform
Return on Equity:
ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency.
Outperform
Debt to Equity:
evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn.
Underperform
Stock Basics & Statistics
Exchange:
AMEX
Sector:
Healthcare
Industry:
Medical - Diagnostics & Research
Shares Out 0 (M)
Shares Float 92 (M)
Held by Insiders 7.257e+007 (%)
Held by Institutions 21.4 (%)
Shares Short 382 (K)
Shares Short P.Month 0 (K)
Stock Financials
EPS -3.164e+007
EPS Est Next Qtrly 0
EPS Est This Year 0
EPS Est Next Year 0
Book Value (p.s.) 0
Profit Margin 0 %
Operating Margin -1 %
Return on Assets (ttm) 766.1 %
Return on Equity (ttm) -100.9 %
Qtrly Rev. Growth 976520 %
Gross Profit (p.s.) 74.77
Sales Per Share 0
EBITDA (p.s.) 0
Qtrly Earnings Growth -0.5 %
Operating Cash Flow 0 (M)
Levered Free Cash Flow -17 (M)
Stock Valuations
PE Ratio -0.01
PEG Ratio 0
Price to Book value 0
Price to Sales 0
Price to Cash Flow -2.08
Stock Dividends
Dividend 0
Forward Dividend 448930
Dividend Yield 0%
Dividend Pay Date Invalid DateTime.
Ex-Dividend Date Invalid DateTime.

StockChart iOS

StoxlineLite iOS

StoxlineLite iOS

OptionCalc iOS

StockChart Android

StoxlineLite Android

StoxlinePro Android

OptionCalc Android